{
    "2018-05-08": [
        [
            {
                "time": "2018-03-31",
                "original_text": "Intercept (ICPT) Q1 Loss Narrower Than Expected, Sales Lag",
                "features": {
                    "keywords": [
                        "Intercept",
                        "Q1",
                        "Loss",
                        "Narrower",
                        "Expected",
                        "Sales",
                        "Lag"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-03-31",
                "original_text": "Celgene’s Pomalyst Saw 24% Growth in 1Q18 Compared to 1Q17",
                "features": {
                    "keywords": [
                        "Celgene",
                        "Pomalyst",
                        "Growth",
                        "1Q18",
                        "1Q17"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-03-31",
                "original_text": "Amgen’s Blincyto and Parsabiv in 1Q18",
                "features": {
                    "keywords": [
                        "Amgen",
                        "Blincyto",
                        "Parsabiv",
                        "1Q18"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-01",
                "original_text": "Will Elanco’s Top-Line Growth Return in 2018?",
                "features": {
                    "keywords": [
                        "Elanco",
                        "Top-Line",
                        "Growth",
                        "Return",
                        "2018"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "agriculture",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-01",
                "original_text": "The Swiss Stock Market",
                "features": {
                    "keywords": [
                        "Swiss",
                        "Stock",
                        "Market"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "general market"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-01",
                "original_text": "It's Raining FDA Approvals, MSON Muscling Up, RDHL To Report Data In Aug.",
                "features": {
                    "keywords": [
                        "FDA",
                        "Approvals",
                        "MSON",
                        "Muscling",
                        "RDHL",
                        "Report",
                        "Data",
                        "Aug"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}